In 2024, Stephen Griffin earned $591.34K in total compensation at Anika Therapeutics, including $278.85K salary and $300.00K bonus. 1+ years at the helm of Anika Therapeutics.
Compensation History
Annual executive compensation data for Stephen Griffin, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$591.34K
Salary
$278.85K
Bonus
$300.00K
Other
$12.49K
Salary
$278.85KBoard Justification
The Compensation Committee uses the compensation philosophy described above, including its informed judgment, and takes into account our performance, competitive market practices, past and expected individual performance achievements, past and expected contributions to overall Company performance, and the need to attract and retain talented executives who can drive and implement our growth and operational excellence strategies in an extremely competitive environment.
Bonus
$300.00KBoard Justification
Mr. Griffin received 100% of his 2024 bonus eligibility per his offer letter as entered into with the Company in May 2024. The Compensation Committee determined an achievement level of 80% for the financial goals, which were weighted at 70% of the total, and an achievement level of 75% for the strategic goals, which were weighted at 30% of the total. As such, the Compensation Committee determined that a corporate bonus payout of 78% of target appropriately reflected the results achieved by the management team in 2024.
Other Compensation
$12.49KBoard Justification
Matching contributions to our Employee Savings and Retirement Plan (401(k) Plan).
Restricted Stock
Board Justification
N/A
Performance Metrics
The Compensation Committee determines the bonus amounts awarded based upon the Company’s achievement of the annual goals and objectives as reviewed and approved by the Board of Directors each year, along with an assessment of both our business and individual NEO performance. The Compensation Committee considers factors such as our financial performance, our overall operational performance, and our contribution to increasing stockholder value to determine an appropriate level of achievement against corporate goals and associated baseline cash bonus compensation for our NEOs.
Stephen Griffin
CEO of Anika Therapeutics
Sector of Economy
Healthcare
CEO of Anika Therapeutics for
1 year 6 months (Jun 2024 - Present)
Previous Experience
Unknown
Other Anika Therapeutics CEOs
Holdings
Track Stephen Griffin's stock holdings and portfolio value over time.
Insider Trading
Stephen Griffin's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Stephen Griffin with competitor CEOs and industry peers.